Doxorubicin vs epirubicin, report of a second-line randomized phase II/III study in advanced breast cancer
- 1 June 1998
- journal article
- clinical trial
- Published by Springer Nature in British Journal of Cancer
- Vol. 77 (12) , 2257-2263
- https://doi.org/10.1038/bjc.1998.375
Abstract
No abstract availableKeywords
This publication has 18 references indexed in Scilit:
- Decreased efficacy of cyclophosphamide, epirubicin and 5-fluorouracil in metastatic breast cancer when reducing treatment duration from 18 to 6 monthsEuropean Journal Of Cancer, 1993
- Epirubicin and doxorubicin: a comparison of their characteristics, therapeutic activity and toxicityCancer Treatment Reviews, 1993
- A prospective randomized comparison of epirubicin and doxorubicin in patients with advanced breast cancer.Journal of Clinical Oncology, 1985
- Randomized phase II trial of carminomycin versus 4'-epidoxorubicin in advanced breast cancer.Journal of Clinical Oncology, 1984
- Toxic and Therapeutic Activity of 4'-Epi-DoxorubicinTumori Journal, 1982
- A PHASE-I TRIAL OF 4'-EPI-ADRIAMYCIN1981
- Risk Factors for Doxorubicin-lnduced Congestive Heart FailureAnnals of Internal Medicine, 1979
- Anthracycline derivatives in new drug development programs.1979
- Assessment of response to therapy in advanced breast cancer.A project of the programme on clinical oncology of the International Union against Cancer, Geneva, SwitzerlandCancer, 1977
- Combination chemotherapy and adriamycin in patients with advanced breast cancer.A Southwest Oncology Group studyCancer, 1976